Evidence map›Paper›PMID 35082637›Full record

ArticleCase reports in oncology

Multiple Colorectal Mucosa-Associated Lymphoid Tissue Lymphoma Successfully Treated with Chemotherapy.

Makoto Saito, Shihori Tsukamoto, Takashi Ishio, Emi Yokoyama, Koh Izumiyama, Akio Mori, Masanobu Morioka, Takeshi Kondo, Hirokazu Sugino

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Makoto SaitoDepartment of Internal Medicine and Hematology/Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Shihori TsukamotoDepartment of Internal Medicine and Hematology/Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Takashi IshioDepartment of Internal Medicine and Hematology/Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Emi YokoyamaDepartment of Internal Medicine and Hematology/Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Koh IzumiyamaDepartment of Internal Medicine and Hematology/Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Akio MoriDepartment of Internal Medicine and Hematology/Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Masanobu MoriokaDepartment of Internal Medicine and Hematology/Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Takeshi KondoDepartment of Internal Medicine and Hematology/Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Hirokazu SuginoDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Hokkaido University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The standard treatment for colorectal mucosa-associated lymphoid tissue (MALT) lymphoma has not yet been established due to the rarity of the disease. Here, we report a case of long-term response to chemotherapy for colorectal MALT lymphoma (stage I). A 77-year-old frail female patient with diabetes mellitus and dementia developed melena of unknown etiology, and a colonoscopy was performed at a nearby hospital. A biopsy suggested malignant lymphoma, and she was referred to our department. As a result of re-examination of colonoscopy, a total of 3 submucosal tumor-like lesions were confirmed. Of these, a biopsy of the lesions in the ascending colon and rectum was performed, and MALT lymphoma was diagnosed on the basis of the histopathological findings. Following close examination, no other lymphoma lesions were found, and the patient was diagnosed with primary colorectal MALT lymphoma, stage I. After 1 course of R-THP-COP chemotherapy (rituximab + cyclophosphamide, pirarubicin, vincristine, and prednisone), the rectal lesion was confirmed to have almost disappeared endoscopically, and lymphoma cells were not found histopathologically. The patient was determined to be in complete remission (CR). However, due to hematological toxicity and a slight worsening of glucose control, the second chemotherapy course was changed to the BR regimen (rituximab + bendamustine), and 4 courses were performed (5 total courses of chemotherapy). Currently, >3 years have passed since reaching CR, and the patient is alive without recurrence.

Indexed as

ChemotherapyColorectal lymphomaMucosa-associated lymphoid tissue lymphomaTreatment

Identifiers

PMID35082637
PMCPMC8739633
OpenAlexW4200098139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.